FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMedexus Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MDP.TO
Medexus Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Medexus Pharmaceuticals Inc. (MDP.TO) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMDP.TO
MDP.TO
Medexus Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
MDP.TO
  1. Home
  2. Stocks
  3. Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc.

🇨🇦MDP.TO•TSX

Medexus Pharmaceuticals Inc.

🇨🇦MDP.TO•TSX
Market cap
$187.61M

Your view on MDP.TO

Mkt Cap
$187.61M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Medexus Pharmaceuticals Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Kenneth d'Entremont
Headquarters
35 Nixon Road, Bolton, ON, CA
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Kenneth d'Entremont
Headquarters
35 Nixon Road, Bolton, ON, CA
Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy.

The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.

Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms.

The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Medexus Pharmaceuticals Inc. from FRC's valuation model, read against the market price. MDP.TO last traded at C$5.97; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Medexus Pharmaceuticals Inc.. Starting points for Medexus Pharmaceuticals Inc.: EPS -C$0.04, beta 1.68 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Medexus Pharmaceuticals Inc.. Trailing twelve-month EPS for Medexus Pharmaceuticals Inc. stands at -C$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026

Hold

Analyst ratings

1 rating
  • Strong Buy0
  • Buy0
  • Hold1
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Mar 2027Next yearYear to Mar 2028
Average estimate$0.07$0.08$0.20$0.59
Lowest estimate$0.03$0.05$0.16$0.43
Highest estimate$0.10$0.11$0.26$0.81
Number of analysts3344
A year ago$0.001−$0.111−$0.071—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Mar 2027Next yearYear to Mar 2028
Average estimate$30.90M$31.17M$120.56M$144.21M
Lowest estimate$26.07M$28.67M$118.51M$136.74M
Highest estimate$33.50M$32.21M$121.57M$148.67M
Number of analysts5556
A year ago$25.32M$24.65M$99.33M—
Growth vs a year ago+22.0%+26.4%+21.4%—
Recent rating and target changes (3)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Medexus Pharmaceuticals Inc.. Medexus Pharmaceuticals Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MDP.TO19 companies · 3 funds
Compare MDP.TO with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
BNXT.CNBioNxt Solutions Inc.HealthcareDrug Manufacturers - Specialty & Generic$76.7M
CRDL.TOCardiol Therapeutics Inc.HealthcareDrug Manufacturers - Specialty & Generic$164.1M
CXXI.CNC21 Investments Inc.HealthcareDrug Manufacturers - Specialty & Generic$58.4M
DB.VDecibel Cannabis Company Inc.HealthcareDrug Manufacturers - Specialty & Generic$54.4M
IAN.CNiAnthus Capital Holdings, Inc.HealthcareDrug Manufacturers - Specialty & Generic$34.1M
INNO.CNInnoCan Pharma CorporationHealthcareMedical - Pharmaceuticals$36.1M
MRMD.CNMariMed Inc.HealthcareDrug Manufacturers - Specialty & Generic$51.4M
More Medical - Pharmaceuticals companies
TickerTypeCompanySectorExchangeMkt cap
SBMFFSino Biopharmaceutical LimitedHealthcareOTC$15.0B
SCNXScienture Holdings, Inc.HealthcareNASDAQ$4.1M
SCYXSCYNEXIS, Inc.HealthcareNASDAQ$17.7M
SDEVStablecoin Development Corp.HealthcareAMEX$29.7M
SDGCFSundrug Co.,Ltd.HealthcareOTC$3.3B
SGIPFSugi Holdings Co.,Ltd.HealthcareOTC$2.9B
SHMNSOHM, Inc.HealthcareOTC$1.9M
SKVISkinvisible, Inc.HealthcareOTC$1.1M
SNNCSibannac, Inc.HealthcareOTC$197,600
SPPHSpencer Pharmaceutical Inc.HealthcareOTC$29,436
SYDRFDelota Corp.HealthcareOTC$2.9M
SYMQYSymBio Pharmaceuticals LimitedHealthcareOTC$27.2M
ETFs holding Medexus Pharmaceuticals Inc.
TickerFundFund assets% of the fund
DFICDimensional - International Core Equity 2 ETF$15.4B in assets0.00%
DFAXDimensional - World ex US Core Equity 2 ETF$11.7B in assets0.00%
EGIF.TOExemplar Growth and Income Fund$3M in assets0.93%

Largest holders first, then the funds most concentrated in MDP.TO.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Medexus Pharmaceuticals Inc.. Coverage tracks Medexus Pharmaceuticals Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Medexus Pharmaceuticals Inc.

MDP.TO AnalysisFair
Past
5
Growth
1
Health
3
Profit
1
Value
1